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Purpose: To assess the improvement of concurrent erectile dysfunction (ED) in men
with overlap syndrome (obstructive sleep apnea and chronic obstructive pulmonary
disease), treated with continuous positive airway pressure (CPAP) and bronchodi-
lators.
Material and methods: We evaluated 48 men of a mean age of 52.8710 years
suffering from both obstructive sleep apnea (OSA) and chronic obstructive
pulmonary disease (COPD), and concurrent ED. They were treated with conventional
for pulmonary obstruction therapy (CPAP and bronchodilators) for 6 months and then
their erectile function (EF) status was reassessed. ED was considered as improved, if
ED intensity score increased for at least five points compared to that of baseline. The
determinants for improvement of ED were also evaluated, as well as patient’s
personal degree of satisfaction with the treatment they received as far as the
disorder was concerned.
Results: EF was improved in 12 patients (25%), but only two thirds of them were
satisfied with the grade of improvement after treatment. ED improvement was
related positively with age and apnea/hypopnea index and negatively with ED
duration. ED intensity score, O2 saturation at night and BMI were not significantly
related to the outcome of EF improvement.
Conclusions: Conventional treatment for OSA and COPD, has a positive effect on




Long-term conventional treatment for overlap syndrome 211improvement of respiration during sleep with CPAP and of oxygenation with
bronchodilators continuously. Of the improved men, one third was not satisfied with
the impact of this treatment modality on their EF. It is likely that specific for ED
treatment is needed in these individuals.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnea (OSA) syndrome is char-
acterized by repetitive episodes of upper airway
obstruction with consequent blood oxygen desa-
turation, sleep fragmentation and excessive day-
time somnolence.1 Diagnosis is based on an
overnight polysomnographic examination, during
which hypoxic episodes, hypercapnia, transient
awakening and fragmented sleep are recorded.2 It
is associated with obesity, hypertension and cardi-
ovascular disease. Although the etiologic associa-
tion between OSA and sexual disorders is
controversial, it has been reported that the
impairment of sacral segment function in OSA
patients leads to the development of male sexual
dysfunction.3 However, sexual problems are com-
monly found in patients with sleep disorders and
vice versa.4,5
Chronic obstructive pulmonary disease (COPD) is
a respiratory disorder resulting in many extra-
pulmonary consequences. There is evidence that
COPD is associated with sexual dysfunction and
especially erectile dysfunction (ED), and that
chronic respiratory failure worsening results in
further sexual insufficiency.6 In a national survey
among patient associations, the rate of sexual
dysfunction was approximately 40% in patients with
chronic respiratory disorders.7 Overlap syndrome
(OS), a term introduced by Flenley,8 describes the
association and simultaneous presence of OSA and
COPD. The prevalence of OSA in the community is
reportedly about 4% in adult males of the fourth
and fifth decade, and that of COPD is 1% of the
general population.9 OS in recent studies has a
prevalence of 11% amongst patients with OSA and
14% amongst patients with mild COPD. The combi-
nation of the two disorders enhances the effect of
each of them on nocturnal hypoxemia and O2
desaturation.10
ED, has been defined by the NIH as the inability to
achieve and maintain an erection sufficient for sexual
intercourse. Its association with OSA and COPD7,11
raises interest about the natural history and treat-
ment of ED in cases with OS. In this study, we assessed
the impact of conventional treatment, namely
continuous positive airway pressure (CPAP) and
bronchodilators, on concurrent ED in men with OS.Material and methods
Between January 2003 and February 2005, 720 new
patients were diagnosed with COPD, in the out-
patient clinic of the Pneumonology Department.
Two hundred and thirty five of them had stage 2 and
3 COPD (FEV1/FVCo70% and FEV1o50%), diagnosed
according to the criteria of the European Respira-
tory Society.12 Forced spirometry was done using a
Morgan Flexiflo RS23C Interface spirometer (P.K.
Morgan, UK). Patients with daytime sleepiness were
also evaluated by Epworth sleepiness scale (ESS)
and when the score was 410, they underwent a
full-night polysomnography examination in the
sleep laboratory. Of those 235 patients, a total of
74 suffered also from OSA (apnea/hypopnea index
(AHI)45, snoring, sleep fragmentation and daytime
somnolence). Digital PSG recordings Systems (Som-
nostar a Series; Sensor-Medics, Inc; Yorba Linda,
CA, USA) were used. The following variables
monitored: electroencephalogram (EEG, two para-
central, two frontal, two occipital) submental
electromyogram (EMG), right and left electroculo-
gram (ROC, LOC). Oronasal airflow was recorded by
thermistors mounted over the nose and mouth and
respiratory efforts were recording by piezo-electric
bands. Arterial oxygen saturation (SaO2) was
measured continuously via a non-invasive infrared
finger probe. Electrocardiography (ECG) was re-
corded continuously between the forearms. The
surface EMGs of both anterior tibial muscles were
also recorded. The data received from the poly-
graph was digitally encoded and stored on a
removable optical-laser-disc. The stored data was
immediately available for study and scoring. PSG
were scored manually using standard criteria for
sleep stages.13 An apnea was defined as a cessation
of airflow lasting at least 10 s, accompanied by a
dropped of SaO2 by more than 2% below the
immediately preceding baseline.14 Hypopnea was
defined as a decrease of the airflow by a drop of
SaO2 by more than 2% below the immediately
preceding baseline. CPAP titration was manually
performed in the sleep laboratory during a poly-
somnographic study. Optimal CPAP was considered
the lowest level of pressure that eliminated almost
all obstructive respiratory events, including flow
limitation events, in all body positions and in all
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received CPAP therapy. According to the guideline
for the management of COPD:2004 Revision,15
bronchodilators used were the anticholinergic
tiotropium once daily, the beta-agonists salmeterol
and formoterol twice daily, and occasionally the
methyloxanthine, theophylline. Of the 74 patients
with OS, 60 suffered from concurrent ED which had
been diagnosed clinically, during diagnostic work up
for pulmonary obstruction, when the ED intensity
score16 was p20 (Appendix). Patients with hormo-
nal deficiencies or penile deformities and patients
who were receiving or had received any medication
for ED during the last month were excluded from
the study. Thus, of the 60 patients that fulfilled the
criteria for inclusion in the present study (COPD+O-
SA+ED), 48 participated while 12 were excluded or
did not show interest in participating, for various
personal reasons. Enrollment process of patients
assessed for COPD, OSA and ED is depicted in Fig. 1.
After a 6-month treatment, the status of their
erectile function was reassessed by ED intensity
score. ED was considered as improved, if ED score
increased at least five points compared to that of
baseline. The five points cut off point was selected
because it generally designates an individual
change in ED severity scale. This must not be720 pts assessed for COPD
235 pts had COPD stage 2 and 3
74 pts had OS
60 pts had OS and ED
48 pts participated in the study
Figure 1 Enrollment process of patients assessed for
COPD, OSA and ED.confused with the overall change in ED score that
patients reported as a group. Patients were also
asked to answer with ‘yes’ or ‘no’ if they were
satisfied with the effect of therapy on their sexual
function.
Primary outcomes were the difference in ED
intensity score and the evaluation of the improve-
ment of erectile function, as well as the satisfac-
tion of the patients with treatment. Secondarily,
we evaluated the impact of age, body mass index
(BMI), AHI, ED duration and nocturnal O2 saturation
on the improvement of the disorder.
After testing data for normality, statistical
analysis was performed using the Wilcoxon signed
ranks test, the Mann–Whitney test and w2 test. A
forward stepwise logistic regression was used to
assess the determinants for improvement of erec-
tile function. Statistical significance was accepted
at all times when Po0.05. A commercially avail-
able statistical package was used to perform the
analysis (SPSS 12.0 for Windows).Results
Mean7SD values of the studied men were for age
52.8710 years, ED duration 16.8716 months, AHI
28.3723.2, BMI 33.874.3, O2 saturation at night
90.7673.6% and ED intensity score 16.171.5.
Demographics at baseline are shown in Table 1.
All patients were overweight and heavy smokers,
and had COPD of moderate severity.
ED intensity score was improved in 12 (25%) of
the studied patients, while the remaining 36
patients (75%) did not report an improved ED
intensity score. Of the patients who experienced
erectile function improvement, only 8 (16.6% of the
studied population) were satisfied with their
erectile function after treatment. Nevertheless,
in the whole population of patients, improvement
in ED was significant (Wilcoxon signed ranks test,
Po0.001), but the patients, except of the above
mentioned, were not satisfied with the effect of
the treatment they received on their erectile
function (w2 Po0.001). Erectile function improve-
ment was related positively with age and AHI and
negatively with ED duration, while ED score, O2
saturation at night and BMI had a small and non-
significant relation to the outcome of ED improve-
ment. Stepwise multiple regression analysis pro-
duced a model predicting ED improvement that
included age, AHI and ED duration, although a
model with ED duration alone was not predictive of
the outcome of the treatment (Hosmer–Lemeshow
statistic w2 ¼ 12.191, P ¼ 0.007). The Hosmer–Le-
meshow statistic indicated a good fit for the model
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Table 1 Demographics at baseline, for all patients and for the two groups of EF improvement outcome
(mean7SD).
Improvement No improvement All patients
Age (years) 58.2577.9 51710.1 52.8710
Body mass index 34.8573.4 33.474.5 33.874.3
Apnea hypopnea index 44.9729.9 22.7717.8 28.3723.2
Sat O2% (nocturnal) 89.3575.4 91.272.7 90.7673.6
ED duration (months) 18.75713.7 16.17716.8 16.8716










Figure 2 Age of the two groups of patients regarding ED
improvement (P ¼ 0.031).
Long-term conventional treatment for overlap syndrome 213(w2 ¼ 9.08, P ¼ 0.247). The model was able to
correctly predict 94.4% of the patients who would
not improve and 58.3% of the patients who would,
for an overall success rate of 85.4%. Employing a
0.05 criterion of statistical significance, age, AHI
and ED duration had significant partial effects. The
odds ratio for age indicated that when holding all
other variables constant, 1 year increase in age
gave a 1.34-fold increase in the odds for improving,
one point higher AHI increased by 1.08 the odds for
improving while 1 month longer ED duration
decreased the odds for improving (OR ¼ 0.88).
In bivariate analysis, the patients that improved
were older (P ¼ 0.031, Fig. 2), had a higher AHI
(P ¼ 0.006, Fig. 3), a lower ED intensity score
before treatment (P ¼ 0.002) and a higher score
after treatment (Po0.001) than the others. The
BMI (P ¼ 0.315), O2 Saturation (P ¼ 0.782) and ED
duration (P ¼ 0.221) before treatment did not
differ significantly between the two groups.Discussion
OSA could be described as the intermittent failure
to transport the full complement of nasal nitric
oxide (NO) to the lung with each breath.17 Thus,
the dearth of NO has been implicated for the
development of the OSA consequences.18,19 The
long-term complications of OSA, namely hyperten-
sion, atherosclerosis and coronary artery disease,
which are in parallel associated with ED itself,20
may be due to the repeated temporary dearth of
NO in the tissues, secondary to a lack of oxygen,
one of NO’s two essential substrates.17 The impair-
ment of NO’s vasoprotective function due to the
respiratory disturbances during nighttime sleep
might explain an etiologic association between
OSA and ED. A number of clinical trials have shown
the therapeutic impact of CPAP on the treatment of
OSA. In an earlier study of 15 men with mild OSA
treated for 12 weeks with CPAP, we reported a 24%
success rate in sexual attempts.21 Li et al.22 treated
15 men for 1 month and reported a significant
improvement in erectile function. Margel et al.23
administered CPAP for at least 1 year to 60 patients
with OSA and ED, and showed that 20% of men
improved. In their study, the main predictor of
erectile improvement was OSA severity.
COPD is characterized by partially reversible
chronic airflow limitation, secondary to an abnor-
mal inflammatory reaction in both airways and lung
parenchyma. It is associated with several other
systemic non-pulmonary consequences that add to
the burden of disease and contribute significantly
to a marked decrease in quality of life (QoL).
Although the structural changes in airways and
alveoli remodel the lung, COPD should be viewed by
clinicians as a treatable condition, since most
patients with COPD have an additional reversible
component related to increased bronchomotor
tone.24 ED should be considered as a consequence
of pulmonary obstruction which deserves to be
treated. Long-term oxygen therapy has been
studied for the reversal of sexual disorders in males
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one month and treated successfully impotence in 5
out of 12 patients. The responders showed a
significant increase in arterial pO2 and serum
testosterone, and a decline in sex hormone binding
globulin. Very short oxygen treatment did not
improve impotence, despite a significant increase
in pO2. Walbroehl
26 has reported that the medica-
tions used to alleviate COPD can both help and
hinder sexual functioning. However, the relevant
literature is poor as data reporting on any positive
effect of conventional treatment for COPD on ED,
besides oxygen, do not exist.
As a primary observation, the results of the
present study suggest that the long term therapy
with bronchodilators and CPAP of a specific group of
men with OS and concurrent ED may improve the
latter in about 25% of the cases. Interestingly, the
improvement of ED in patients with OSA treated
with CPAP has been reported between 20% and
33%,21,23 approximately similar with the above
mentioned. It must be postulated, that this
improvement may be due to the improvement of
oxygenation during sleep with CPAP and of respira-
tory function with bronchodilators continuously.
One of the mechanisms proposed to be responsible
for the ED in patients with OSA and/or COPD is
endothelial dysfunction with overproduction of
endothelin27,28 and impaired NO availability in the
peripheral blood.29,30 Several studies have shown
that continuous treatment with CPAP increases the
levels of NO in OSA patients.29,31 Additionally, the
administration of bronchodilators improves expira-
tory airflow by reducing airway muscle tone.
Tiotropium, a newer anticholinergic agent, dissoci-
ates slowly from M3 receptors (34.7-h half-life)
resulting in a high and constant 24-h bronchodilator
activity.32 Beta-agonists salmeterol and formoterol,
compared to placebo, have both demonstrated
greater FEV1, an index of airway caliber response,
and peak expiratory flow improvement.33 Theo-
phylline, a nonselective phosphodiesterase (PDE)
inhibitor, increases cyclic adenosine monopho-
sphate and thus, relaxes the bronchomotor tone
and produces systemic and pulmonary vascular
dilatation. However, the successful targeting of
PDE5 in the treatment of ED, irrespectively of the
underlying pathology, with sildenafil and the newer
PDE5 inhibitors, vardenafil and tadalafil, provides
rational concept for the targeting of PDE in COPD
treatment. The positive results from recent clinical
trials examining the efficacy of selective PDE4
inhibitors, cilomilast and roflumilast, offer some
optimism.34 Because of their class, it will be
interesting to assess the impact of these agents
on concurrent ED.ED improvement was positively influenced by
patient age and AHI, and negatively by ED duration.
The fact that older patients are more likely to
improve erectile function with treatment for OS
may be due to lower expectations that older men
have from their sexual life, so they easily capitalize
any improvement of their sexual function. AHI was
also found to be a determinant for improvement in
a relative study of long term treatment with CPAP
for patients with OSA and ED,23 underlining the
common clinical observation that the more severe
pulmonary obstruction the higher improvement of
concurrent ED. A longer duration of ED may reduce
the residual erectile capacity in these individuals
explaining the negative predictive role of this
parameter. This must be taken into consideration
by physicians in order to diagnose as early as
possible ED in men with OS and manage it
accordingly. However, the pathway of ED in OS,
the mechanism of erectile function improvement
with conventional treatment and the therapeutic
impact of combinations of bronchodilators must be
studied further in larger series of patients.
Sexual changes in males with chronic respiratory
failure affect significantly not only patient QoL but
also the quality of the relationship and the level of
communication in the couple.6 Improvement of
subsequent sexual dysfunction must be one of the
secondary goals of therapy as a health-related QoL
(HRQoL) issue. The mean ED intensity score of the
whole studied population was significantly higher
after treatment compared to baseline, but the
majority was not satisfied with erectile function
status, as only one fourth of them crossed the five
points improvement cut off change. Furthermore,
one third of patients among those who had a higher
than five points improvement were not satisfied
with treatment impact on their sexual function. It
is concluded therefore, that the observed improve-
ment in ED score was not projected as a clinical
improvement, either because of higher expecta-
tions or because of a still low score after
treatment. Obviously, the status of sexual health
and the relative satisfaction are influenced by
satisfaction with treatment for the underlying
pathology and relief of symptoms, and compliance
with treatment. Thus, conclusions for satisfaction
with treatment must be expressed cautiously unless
well-designed studies assessing these particular
parameters will be carried out. However, the
advent of sildenafil, followed by the newer PDE5
inhibitors, revolutionarily changed the therapeutic
management of ED. These agents, irrespectively of
risk factors and comorbidities, influence local
regulatory mechanisms and enhance erection by





















Figure 3 AHI of the two groups of patients regarding ED
improvement (P ¼ 0.006).
Long-term conventional treatment for overlap syndrome 215NO on resistance vessels and trabecular smooth
musculature of corpus cavernosum. The experience
with the use of sildenafil in the treatment of ED
associated with OSA, which was superior in efficacy
and satisfaction with treatment compared to
CPAP,21 suggests that specific for ED treatment
may be needed in these individuals as well. Co-
administration of CPAP, bronchodilators and PDE5
inhibitors would be also of utmost importance to
assess improvement of sexual function and HRQoL
in men with OS.Appendix. Erectile dysfunction intensity
score
Items
1. How often were you able to get an erection
during sexual activity?
2. When you had erections with sexual stimulation,
how often were your erections hard enough for
penetration?
3. When you attempted intercourse, how often
were you able to penetrate your partner?
4. During sexual intercourse, how often were you
able to maintain your erection after you had
penetrated your partner?
5. During sexual intercourse, how difficult was it to
maintain your erection to completion of
intercourse?
Answers
For items 1 to 4 the possible answers are: Almost
never or never; a few times (much less than halfthe time); sometimes (about half the time); most
times (much more than half the time); almost
always or always, and are scored with 1, 2, 3, 4 and
5, respectively.
For item 5 the possible answers are: Extremely
difficult; very difficult; difficult; slightly difficult;
not difficult, and are scored with 1, 2, 3, 4 and 5
respectively.
Total score
Add the scores for items 1–5 (possible maximum:
25).
ED severity
Severe: 5–10; moderate: 11–15; mild: 16–20;
normal: 21–25.References
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